30 closest matches · ranked by relevance
Melanoma
Primary: Objective Response Rate (ORR) in the Full Analysis Set Analysis Population — 45.0 Percentage of participants
Mucosal Melanoma · Acral/Lentiginous Melanoma · Chronically Sun Damaged Melanomas
Primary: Best Overall Response — 0; 0; 0; 7 participants
Melanoma (Skin)
Primary: Objective Response Rate Among KIT-positive Patients — 0.182 proportion of participants
Mucosal Lentiginous Melanoma · Acral Lentiginous Malignant Melanoma
Primary: 2-month Progression-free Survival Rate — .52; .52 proportion of patients
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Metastatic · Uveal Melanoma
Primary: Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival…
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Metastatic Malignant Uveal Melanoma
Primary: Disease Control Rate — 18; 8 Participants
Recurrent Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 — 2; 18; 14; 1 Participants
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
Melanoma
Primary: Number of Participants With T-cell Response to Peptide Vaccine — 6; 1; 12; 19 Participants
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Metastatic Melanoma
Primary: Percentage of Patients With Adverse Events (AEs) — 5; 4; 1; 0 Participants
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Uveal Melanoma
Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Cancer
Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Recurrent Melanoma · Stage IA Skin Melanoma · Stage IB Skin Melanoma
Primary: Percentage of Participants With Successful Intravital Microscopy on Accessible Human Melanoma Tumors During Standard Local Excision — 70 percentage of participants
Melanoma
Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants
Metastatic Malignant Neoplasm in the Liver · Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) — 0; 0; 8; 5 Participants
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants
Melanoma
Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Melanoma
Primary: Objective Response Rate (ORR) — 2; 1 Participants
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants